Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589142 | 0.89 | MEN1 (0.41) | MEN1KMT2AKDM4E | |
| SCHEMBL3588186 | 0.87 | XDH (0.43) | XDHSLC22A12MEN1KMT2A | |
| SCHEMBL3593139 | 0.86 | XDH (0.43) | XDHSLC22A12 | |
| SCHEMBL3587557 | 0.85 | XDH (0.45) | XDHSLC22A12 | |
| SCHEMBL3589529 | 0.85 | XDH (0.51) | XDHSLC22A12CYP11B1CYP11B2 | |
| SCHEMBL3584617 | 0.82 | XDH (0.50) | XDHSLC22A12 | |
| SCHEMBL3593046 | 0.81 | XDH (0.42) | XDHSLC22A12 | |
| SCHEMBL3585744 | 0.81 | XDH (0.49) | XDH | |
| SCHEMBL3587389 | 0.81 | KDM4E (0.45) | XDHSLC22A12KDM4E | |
| SCHEMBL3583722 | 0.81 | XDH (0.41) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | XDH 1/4885SLC22A12 292/4885CYP11B1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.